According to the reviled CIS, more than 90% of the population is in favor of the legalization of medical cannabis.
In a single street in Madrid, we see 2 #CBD franchises, 1 tobacconist, 1 herbalist and 4 pharmacies. In the first 4 the #CBD is very visible in their showcases. In the last 4, no.
What fear grips pharmacies not to bet on a market, which is expected to grow exponentially in the medium term, being a medicinal product?
Why has the pharmacy allowed these and other establishments to advance you?
The argument that it is an unregulated drug is not valid.
First. The Court of Justice of the European Union, on 11/19/20 (Kanavape case), in a binding judgment for the entire EU, declares that CBD does not have psychotropic effects harmful to health and that any prohibition on the use of CBD obtained from the plant as a whole does not meet the ultimate goal of protecting public health.
Second. In a vote of 12/2/20, the UN recognized the medicinal and therapeutic potential of cannabis and its resin included in List I of the Convention, which includes substances that, despite their addictive potential, are not considered harmful to the health and have therapeutic value.
What is missing is the national legislation in this regard, but taking into account the above, the trade of these products for topical use, such as cosmetics, is already allowed.
The AEMPS is in charge of issuing the corresponding licenses, supervises and controls the cultivation of cannabis for medical or research purposes, as well as the authorization of medicines and cosmetic products containing cannabis derivatives. It strictly adheres to the EU framework, always with a conservative not to say restrictive approach.
Despite everything, in Spain there are numerous production companies that already achieve significant income from the sale of products derived from hemp. This sector is in full development.
Medicinal CBD must be part of the future of pharmacy.
If the sector renounces NOW to promote the analgesic creams and cosmetic oils that are already on the market, TOMORROW the producers of the next cannabis derivatives will look to other channels to distribute their products.
Can the pharmacy afford it?
You have to look to the future without fear and not lose business opportunities.
BeFarmaPro 
Deja un comentario